Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"Veritaz Healthcare","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","amount":"$22.5 million","upfrontCash":"Undisclosed","newsHeadline":"Aurobindo Pharma Buys Veritaz for Rs 171 Crore to Enter Domestic Formulation Business","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Veritaz Healthcare

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Currently, the company caters to anti-infective and pain-management therapeutic areas and has a pipeline of products to enter into the cardio/diabetic and ortho/gynaecology segments, including Veriaz.

            Lead Product(s): Azithromycin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Veriaz

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Aurobindo Pharma Limited

            Deal Size: $22.5 million Upfront Cash: Undisclosed

            Deal Type: Acquisition March 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY